|
FLT3 F594L
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 F594L in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835A
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D835A in culture (PMID: 40196870).
|
40196870
|
|
FLT3 K663R
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 K663R in culture (PMID: 40196870).
|
40196870
|
|
FLT3 Y572C
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 Y572C in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836delinsLD
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I836delinsLD in culture (PMID: 40196870).
|
40196870
|
|
FLT3 F590_Y591delinsGD
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 F590_Y591delinsGD in culture (PMID: 40196870).
|
40196870
|
|
FLT3 N841I
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 N841I in culture (PMID: 40196870).
|
40196870
|
|
FLT3 F590_D593delinsLY
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 F590_D593delinsLY in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835V
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835V in culture (PMID: 40196870).
|
40196870
|
|
FLT3 N841Y
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 N841Y in culture (PMID: 40196870).
|
40196870
|
|
FLT3 Y842C
|
hematologic cancer
|
resistant
|
Quizartinib
|
Preclinical |
Actionable |
In a preclinical study, cells expressing FLT3 Y842C were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 D835E
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D835E in culture (PMID: 40196870).
|
40196870
|
|
FLT3 R845S
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 R845S in culture (PMID: 40196870).
|
40196870
|
|
FLT3 V592G
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 V592G in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I867S
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I867S in culture (PMID: 40196870).
|
40196870
|
|
FLT3 F590_D593delinsLY
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 F590_D593delinsLY in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836S
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I836S in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835del
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 E598_Y599del
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 E598_Y599del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 R834Q
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 R834Q in culture (PMID: 40196870).
|
40196870
|
|
FLT3 S840_N841insGS
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 S840_N841insGS in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836del
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I836del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836delinsLD
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I836delinsLD in culture (PMID: 40196870).
|
40196870
|
|
FLT3 N676K
|
hematologic cancer
|
decreased response
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FLT3 N676K were less sensitive to Rydapt (midostaurin) compared to cells expressing a FLT3-ITD in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836delinsLD
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I836delinsLD in culture (PMID: 40196870).
|
40196870
|
|
FLT3 V579A
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 V579A in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836S
|
hematologic cancer
|
conflicting
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I836S in culture (PMID: 40196870).
|
40196870
|
|
FLT3 R834Q
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 R834Q in culture (PMID: 40196870).
|
40196870
|
|
FLT3 Y842C
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 Y842C in culture and inhibited growth in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 I836T
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I836T in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D593del
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D593del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836S
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I836S in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836T
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I836T in culture (PMID: 40196870).
|
40196870
|
|
FLT3 F590_D593delinsLY
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 F590_D593delinsLY in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835delinsLK
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835delinsLK in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D839G
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D839G in culture (PMID: 40196870).
|
40196870
|
|
FLT3 V592G
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 V592G in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D839G
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D839G in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836T
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I836T in culture (PMID: 40196870).
|
40196870
|
|
FLT3 K663Q
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 K663Q in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I867S
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I867S in culture (PMID: 40196870).
|
40196870
|
|
FLT3 N841I
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 N841I in culture (PMID: 40196870).
|
40196870
|
|
FLT3 K663R
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 K663R in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835N
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D835N in culture (PMID: 40196870).
|
40196870
|
|
FLT3 N841I
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 N841I in culture (PMID: 40196870).
|
40196870
|
|
FLT3 F590_Y591delinsGD
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 F590_Y591delinsGD in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D593del
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D593del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835E
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D835E in culture (PMID: 40196870).
|
40196870
|
|
FLT3 N841Y
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 N841Y in culture (PMID: 40196870).
|
40196870
|
|
FLT3 N676K
|
hematologic cancer
|
resistant
|
Quizartinib
|
Preclinical |
Actionable |
In a preclinical study, cells expressing FLT3 N676K were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 D835G
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D835G in culture (PMID: 40196870).
|
40196870
|
|
FLT3 V592A
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 V592A in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835del
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 D835del in culture and inhibited growth in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 V592A
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 V592A in culture (PMID: 40196870).
|
40196870
|
|
FLT3 V579A
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 V579A in culture (PMID: 40196870).
|
40196870
|
|
FLT3 V592A
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 V592A in culture (PMID: 40196870).
|
40196870
|
|
FLT3 F590_Y591delinsGD
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 F590_Y591delinsGD in culture (PMID: 40196870).
|
40196870
|
|
FLT3 K663Q
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 K663Q in culture (PMID: 40196870).
|
40196870
|
|
FLT3 Y572C
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 Y572C in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835V
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 D835V in culture and inhibited growth in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 S840_N841insGS
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 S840_N841insGS in culture (PMID: 40196870).
|
40196870
|
|
FLT3 V579A
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 V579A in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835V
|
hematologic cancer
|
resistant
|
Quizartinib
|
Preclinical |
Actionable |
In a preclinical study, cells expressing FLT3 D835V were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 D835G
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835G in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I867S
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I867S in culture (PMID: 40196870).
|
40196870
|
|
FLT3 E598_Y599del
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 E598_Y599del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 K663R
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 K663R in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835E
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835E in culture (PMID: 40196870).
|
40196870
|
|
FLT3 V592G
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 V592G in culture (PMID: 40196870).
|
40196870
|
|
FLT3 Y842C
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 Y842C in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835G
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D835G in culture (PMID: 40196870).
|
40196870
|
|
FLT3 F594L
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 F594L in culture (PMID: 40196870).
|
40196870
|
|
FLT3 R834Q
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 R834Q in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D839G
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D839G in culture (PMID: 40196870).
|
40196870
|
|
FLT3 Y572C
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 Y572C in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836del
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I836del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 N676K
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 N676K in culture and inhibited growth in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 K663Q
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 K663Q in culture (PMID: 40196870).
|
40196870
|
|
FLT3 R845S
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 R845S in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835N
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D835N in culture (PMID: 40196870).
|
40196870
|
|
FLT3 I836del
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I836del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 S840_N841insGS
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 S840_N841insGS in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835del
|
hematologic cancer
|
decreased response
|
Quizartinib
|
Preclinical |
Actionable |
In a preclinical study, cells expressing FLT3 D835del were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 F594L
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 F594L in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835A
|
hematologic cancer
|
conflicting
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D835A in culture (PMID: 40196870).
|
40196870
|
|
FLT3 N841Y
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 N841Y in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835N
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835N in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835delinsLK
|
hematologic cancer
|
decreased response
|
Quizartinib
|
Preclinical |
Actionable |
In a preclinical study, cells expressing FLT3 D835delinsLK were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 D593del
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D593del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 D835delinsLK
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 D835delinsLK in culture and inhibited growth in a transplant model (PMID: 40196870).
|
40196870
|
|
FLT3 D835A
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835A in culture (PMID: 40196870).
|
40196870
|
|
FLT3 E598_Y599del
|
hematologic cancer
|
sensitive
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 E598_Y599del in culture (PMID: 40196870).
|
40196870
|
|
FLT3 R845S
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 R845S in culture (PMID: 40196870).
|
40196870
|